PHARMACEUTICAL COMPOSITION FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE Russian patent published in 2022 - IPC A61K9/08 A61K39/395 

Abstract RU 2786053 C2

FIELD: medicine; therapy.

SUBSTANCE: invention relates to the field of medicine, namely to therapy; it is intended for the treatment or prevention of a C5-related disease. A method for the treatment of prevention of a C5-related disease includes (a) intravenous administration to an individual of a single intravenous dose of an antibody to C5 at a dose of 500 mg, 1000 mg, or 1500 mg of the antibody, as well as (b) subcutaneous administration to an individual of two or more subcutaneous doses of the antibody to C5 (i) at a dose of 340 mg of the antibody once a week or every two weeks, or (ii) from 600 mg to 2000 mg of the antibody every four weeks. The specified antibody to C5 contains a sequence of a variable domain of a heavy chain (VH), consisting of an amino acid sequence SEQ ID NO: 2, a sequence of a variable domain of a light chain (VL), consisting of an amino acid sequence SEQ ID NO: 6, a sequence of a constant domain of a heavy chain (CH), consisting of an amino acid sequence SEQ ID NO: 13, and a sequence of a constant domain of a light chain (CL), consisting of an amino acid sequence SEQ ID NO: 18.

EFFECT: use of the invention allows for an increase in the efficiency and safety of treatment or prevention of C5-related disease.

11 cl, 10 dwg, 3 tbl, 9 ex

Similar patents RU2786053C2

Title Year Author Number
PHARMACEUTICAL COMPOSITION INTENDED FOR USE FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE AND METHOD FOR TREATMENT OR PREVENTION OF C5-RELATED DISEASE 2019
  • Shinomiya Kenji
  • Gotanda Keisuke
  • Nishimura Jun-Ichi
  • Winter Erica
  • Hsu Joy C.
RU2789389C2
DOSAGE AND REGIMEN FOR TREATING OR PREVENTING C5-RELATED DISEASES BY USING THE ANTI-C5 CROVALIMAB ANTIBODY 2020
  • Sostelli, Aleksandr Antuan Bernar
  • Buatua, Simon Bertran Mari
  • Subre, Antuan
  • Zhaminon, Feliks Greguar Zhazon
  • Jordan, Gregor
  • Busher, Kristof
  • Sharuan, Zhan-Erik
RU2823427C2
C5 ANTIBODIES AND METHODS FOR USING THEM 2016
  • Sampej Dzendziro
RU2742606C2
ANTI-C5 ANTIBODIES AND METHODS FOR THEIR USE 2017
  • Rujke Esinao
  • Sampej Dzendziro
RU2789788C2
METHODS FOR TREATING CONDITIONS ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION 2012
  • Demopulos Gregori A.
  • Dadler Tom
  • Shveble Khans-Vilkhelm
RU2662563C2
C5 ANTIBODY AND METHOD FOR PREVENTING AND TREATING COMPLEMENT-RELATED DISEASES 2014
  • Chung Dzunkho
  • Kim Khiori
  • Li Khva Kioung
  • Yang Von Dzun
RU2663349C2
POLYPEPTIDES BINDING TO HUMAN COMPLEMENT C5 2013
  • Bergkhard Sharlotta
  • Berglund Magnus
  • Stremberg Patrik
  • Lindborg Malin
  • Gunneriusson Elin
  • Feldvish Joakhim
RU2654668C2
COMPLEMENT ACTIVITY MODULATORS 2016
  • Demarco, Steven James
  • Hoarty, Michelle Denise
  • Parker, Grace Victoria
  • Ricardo, Alonso
  • Tobe, Sylvia
  • Treco, Douglas A.
RU2733720C2
AGENT FOR DISEASE TREATMENT 2009
  • Ajgner Zil'Ke
  • Germer Mattias
  • Osterrot Frank
  • Uehrek Kristof
  • Kraus Ehl'Mar
  • Vartenberg-Demand Andrea
  • Vol'F Daniehle
  • Kajzer Zibille
  • Lindner Jurgen
  • Brjukher Kristof
  • Delken Benzhamin
RU2540018C2
COMPLEMENT ACTIVITY MODULATORS 2016
  • Demarco, Steven James
  • Hoarty, Michelle Denise
  • Parker, Grace Victoria
  • Ricardo, Alonso
  • Tobe, Sylvia
  • Treco, Douglas A.
RU2769701C2

RU 2 786 053 C2

Authors

Shinomiya Kenji

Yoneyama Koichiro

Shibahara Norihito

Tsuboi Yoshinori

Fukuzawa Taku

Haraya Kenta

Sampei Zenjiro

Bogman Katrijn

Charoin Jean Eric

Dates

2022-12-16Published

2018-01-31Filed